# Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

> **NCT07009457** · PHASE1 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Widespread Small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-1316 (sc) Injection
- **DRUG:** SHR-1316 Injection
- **DRUG:** Carboplatin Injection
- **DRUG:** Etoposide Injection

## Key facts

- **NCT ID:** NCT07009457
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2025-09
- **Final completion:** 2028-09
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009457, "Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07009457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*